These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36102906)

  • 1. Medicines for Europe - 16th Legal Affairs Conference (June 29-July 1, 2022 - Barcelona, Spain).
    Tumminello M
    Drugs Today (Barc); 2022 Sep; 58(9):457-462. PubMed ID: 36102906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Joint 24th Medicines for Europe and 21st International Generic and Biosimilars Association (IGBA) Annual Conference (June 13-15, 2018 - Budapest, Hungary).
    Cross G
    Drugs Today (Barc); 2018 Aug; 54(8):499-505. PubMed ID: 30209444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of biosimilar medicines in Spain: market dynamics, policies, evidence-based insights and avenues for a sustainable market.
    Río-Álvarez I; Cruz-Martos E
    Expert Opin Biol Ther; 2024 Jul; 24(7):583-597. PubMed ID: 38842367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Spanish generic medicines retail market: recommendations to enhance long-term sustainability.
    Dylst P; Vulto AG; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2014 Jun; 14(3):345-53. PubMed ID: 24758569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
    O'Callaghan J; Barry SP; Bermingham M; Morris JM; Griffin BT
    Eur J Clin Pharmacol; 2019 Jan; 75(1):1-11. PubMed ID: 30187103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National and transnational drug shortages: a quantitative descriptive study of public registers in Europe and the USA.
    Ravela R; Lyles A; Airaksinen M
    BMC Health Serv Res; 2022 Jul; 22(1):940. PubMed ID: 35869486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Policies for biosimilar uptake in Europe: An overview.
    Moorkens E; Vulto AG; Huys I; Dylst P; Godman B; Keuerleber S; Claus B; Dimitrova M; Petrova G; Sović-Brkičić L; Slabý J; Šebesta R; Laius O; Karr A; Beck M; Martikainen JE; Selke GW; Spillane S; McCullagh L; Trifirò G; Vella Bonanno P; Mack A; Fogele A; Viksna A; Władysiuk M; Mota-Filipe H; Meshkov D; Kalaba M; Mencej Bedrač S; Fürst J; Zara C; Skiöld P; Magnússon E; Simoens S
    PLoS One; 2017; 12(12):e0190147. PubMed ID: 29284064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of the evolution in the access to orphan medicines in Spain].
    Mestre-Ferrándiz J; Iniesta M; Trapero-Bertran M; Espín J; Brosa M
    Gac Sanit; 2020; 34(2):141-149. PubMed ID: 31014554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value added medicines: what value repurposed medicines might bring to society?
    Toumi M; Rémuzat C
    J Mark Access Health Policy; 2017; 5(1):1264717. PubMed ID: 28265347
    [No Abstract]   [Full Text] [Related]  

  • 11. Dynamics of biosimilar uptake in emerging markets.
    Chhabra H; Mouslim MC; Kashiramka S; Rathore AS
    Expert Opin Biol Ther; 2022 Jun; 22(6):679-688. PubMed ID: 35535988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug shortages in European countries: a trade-off between market attractiveness and cost containment?
    Pauwels K; Huys I; Casteels M; Simoens S
    BMC Health Serv Res; 2014 Sep; 14():438. PubMed ID: 25257912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European Generic Medicines Association (EGA)--16th Annual Conference.
    Kennedy B
    IDrugs; 2010 Aug; 13(8):530-3. PubMed ID: 20721822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Market entry of biosimilar low-molecular-weight heparins in Europe: opportunities and challenges.
    Simoens S; Huys I
    Semin Thromb Hemost; 2013 Apr; 39(3):250-7. PubMed ID: 23235959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
    Moorkens E; Vulto AG; Huys I
    MAbs; 2020; 12(1):1743517. PubMed ID: 32306833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilar Medicines Group - 14th Annual Medicines for Europe Conference (April 28-29, 2016 - London, UK).
    Hodgkinson L
    Drugs Today (Barc); 2016 May; 52(5):309-12. PubMed ID: 27376164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barriers and facilitators of exploiting the potential of value-added medicines.
    Petykó ZI; Inotai A; Holtorf AP; Brixner D; Kaló Z
    Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):229-236. PubMed ID: 32321326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consensus statement on the use of biosimilar drugs in immune-mediated diseases in Spain.
    Monte-Boquet E; Florez Á; Alcaín Martínez GJ; Sellas A
    Reumatol Clin (Engl Ed); 2023 Oct; 19(8):446-454. PubMed ID: 37805258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spanish Society of Hospital Pharmacy position paper on biosimilar medicines.
    Martínez-López de Castro N; Matilla-Fernández MB; Fraga-Fuentes MD; Mangues-Bafalluy I; Asensi-Díez R; Cajaraville-Ordoñana G
    Farm Hosp; 2018 Jul; 42(4):180-183. PubMed ID: 29959844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
    Chen B; Nagai S; Armitage JO; Witherspoon B; Nabhan C; Godwin AC; Yang YT; Kommalapati A; Tella SH; DeAngelis C; Raisch DW; Sartor O; Hrushesky WJ; Ray PS; Yarnold PR; Love BL; Norris LB; Knopf K; Bobolts L; Riente J; Luminari S; Kane RC; Hoque S; Bennett CL
    Oncologist; 2019 Apr; 24(4):537-548. PubMed ID: 30842244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.